Phytopharm PLC (PYM.L)
29 Apr 2013
|Market Cap (Mil.):||£4.60|
|Shares Outstanding (Mil.):||346.90|
LONDON - British biotech Phytopharm gave up its search for a treatment for Parkinson's Disease using a drug derived from subtropical plants on Tuesday and said it was looking to sell the business.
LONDON, March 26 - British biotech Phytopharm gave up its search for a treatment for Parkinson's Disease using a drug derived from subtropical plants on Tuesday and said it was looking to sell the business.
LONDON, March 26 - Phytopharm PLC : * Strategic review update * No further research and development expenditure will be committed, staff
LONDON - Phytopharm said its major drug hope for treating Parkinson's disease had failed in a clinical trial, the latest British biotech company to disappoint after showing early promise.
* Phytopharm's shares fall more than 80 pct (Adds details, analyst reaction, shares)
LONDON, Feb 18 - Phytopharm PLC : * Results from Cogane (TM) in parkinson's disease clinical trial * Headline results indicated that cogane had no beneficial effects on patients'
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Phytopharm PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.